Which statement about a CYP2C19 *17/*17 genotype is correct according to current CPIC guidelines?

Which statement about a CYP2C19 *17/*17 genotype is correct according to current CPIC guidelines?

• A. Patients convert clopidogrel to an inactive metabolite more than *1/*1; therefore, a decrease in dose is recommended
• B. Patients convert clopidogrel to an active metabolite more than *1/*1, but no change in dose is recommended
• C. Patients convert clopidogrel to an active metabolite less than *1/*1; therefore, a decrease in dose is recommended
• D. Patients convert clopidogrel to an active metabolite less than *1/*1; therefore, an alternative antiplatelet is recommended

Answer: (B)

The statement regarding the CYP2C19 *17/*17 genotype being correct emphasizes the enhanced metabolic activity associated with this genotype. Individuals with the *17 allele are classified as ultrarapid metabolizers of clopidogrel, meaning they convert clopidogrel into its active metabolite more efficiently compared to individuals with the *1/*1 genotype, who are considered extensive metabolizers. Current Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines indicate that patients with the *17/*17 genotype generally achieve higher levels of the active metabolite of clopidogrel, which could theoretically lead to an increased antiplatelet effect. However, the guidelines do not recommend adjusting the dose based on this genotype alone, as the increased metabolism does not necessarily translate to improved clinical outcomes in those patients. Maintaining the standard dosing for patients with this genotype optimally balances effective antiplatelet activity while minimizing the risk of adverse effects, such as bleeding. This understanding of the relationship between the genotype and drug metabolism is critical for personalized medicine, particularly in tailoring antiplatelet therapy for better outcomes in patients requiring such treatment.

The statement regarding the CYP2C19 *17/*17 genotype being correct emphasizes the enhanced metabolic activity associated with this genotype. Individuals with the *17 allele are classified as ultrarapid metabolizers of clopidogrel, meaning they convert clopidogrel into its active metabolite more efficiently compared to individuals with the *1/*1 genotype, who are considered extensive metabolizers.

Current Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines indicate that patients with the *17/*17 genotype generally achieve higher levels of the active metabolite of clopidogrel, which could theoretically lead to an increased antiplatelet effect. However, the guidelines do not recommend adjusting the dose based on this genotype alone, as the increased metabolism does not necessarily translate to improved clinical outcomes in those patients. Maintaining the standard dosing for patients with this genotype optimally balances effective antiplatelet activity while minimizing the risk of adverse effects, such as bleeding.

This understanding of the relationship between the genotype and drug metabolism is critical for personalized medicine, particularly in tailoring antiplatelet therapy for better outcomes in patients requiring such treatment.